Nabriva Therapeutics Expands XENLETA® Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical...
top of page
Search
Erkim Public Relations
- Jun 9, 2022
- 1 min
Er-Kim Partners with Kyowa Kirin to Commercialize Palliative Care Portfolio in Eleven CEE Countries
Sofia, Bulgaria – May, 2022 – Er-Kim, a regional specialty pharmaceutical company, announced today the signature of an exclusive...
Erkim Public Relations
- Mar 1, 2022
- 3 min
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with Er-Kim for its Lead Asset, QRX00
ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty...
Erkim Public Relations
- Feb 10, 2022
- 3 min
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Er-Kim for its Lead Asset, QRX003
ASHBURN, Va., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty...
Erkim Public Relations
- Jan 31, 2022
- 2 min
Aeterna Zentaris & Er-Kim Announce Partnership to Commercialize Macrilen in Eight European Countries
Istanbul, Turkey – January 31, 2022 – Er-Kim, a regional specialty pharmaceutical company, announced today the signature of an exclusive...
bottom of page